M. Galimand, A. Guiyoule, G. Gerbaud, B. Rasoamanana, S. Chanteau et al.,

, Multidrug resistance in Yersinia pestis mediated by a transferable plasmid, New England 436 Journal of Medicine, vol.337, pp.677-80, 1997.

A. Guiyoule, G. Gerbaud, C. Buchrieser, M. Galimand, L. Rahalison et al.,

, Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia 439 pestis, Emerging Infectious Diseases, vol.7, pp.43-51, 2001.

T. V. Inglesby, D. T. Dennis, D. A. Henderson, J. G. Bartlett, M. S. Ascher et al., Plague 441 as a biological weapon -Medical and public health management, Journal of the American 442 Medical Association, vol.283, pp.2281-90, 2000.

A. Derbise, Y. Hanada, M. Khalife, E. Carniel, and C. E. Demeure, Complete Protection against 444 Pneumonic and Bubonic Plague after a Single Oral Vaccination, PLoS Negl Trop Dis, vol.445, p.4162, 2015.
DOI : 10.1371/journal.pntd.0004162
URL : https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0004162&type=printable

G. R. Cornelis, The Yersinia YSC-YOP 'type III' weaponry, Nature Reviews Molecular Cell 447 Biology, vol.3, pp.742-52, 2002.
DOI : 10.1038/nrm932

, Food Drug Administration CfDER. 21CFR601 -Biologics -Part 601: Licencing. Subpart 449 H: Approval of Biological Products when Human Efficacy Studies are not Ethical or Feasible, vol.450

, Food Drug Administration CfDER. 21CFR314 -Drugs for Human Use -Part 314: 452 Applications for FDA approval to market a new Drug -Subpart I: Approval of New Drugs 453 when Human Efficacy Studies are not Ethical or Feasible, vol.454, p.2017

, Office of Regulatory Affairs. Guidance Document -Submission and Information 456 Requirements for Extraordinary Use New Drugs (EUNDs), vol.457, 2014.

M. Cavaleri, A. Thomson, T. Salmonson, and R. J. Hemmings, , p.459

, Medicines Agency experience with investigational medicinal products for Ebola, Clinical 460 Trials, vol.13, pp.101-105, 2016.

S. A. Plotkin, Correlates of protection induced by vaccination. Clinical and vaccine 462 immunology : CVI, vol.17, pp.1055-65, 2010.

L. W. Kummer, F. M. Szaba, M. A. Parent, J. J. Adamovicz, J. Hill et al.,

, Antibodies and cytokines independently protect against pneumonic plague, Vaccine, vol.465, pp.6901-6908, 2008.

M. A. Parent, K. N. Berggren, L. W. Kummer, L. B. Wilhelm, F. M. Szaba et al.,

, Cell-mediated protection against pulmonary Yersinia pestis infection, Infect Immun, vol.468, pp.7304-7314, 2005.

S. T. Smiley, Current challenges in the development of vaccines for pneumonic plague. 470 Expert review of vaccines, vol.7, pp.209-230, 2008.

A. Zauberman, S. Cohen, Y. Levy, G. Halperin, S. Lazar et al., , p.472

, Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation 473 with protective immunity in a mouse model of bubonic plague, Vaccine, vol.26, pp.1616-1641, 2008.

S. F. Little, W. M. Webster, H. Wilhelm, D. Fisher, S. L. Norris et al., Quantitative 475 anti-F1 and anti-V IgG ELISAs as serological correlates of protection against plague in 476 female Swiss Webster mice, Vaccine, vol.28, pp.934-943, 2010.

P. Fellows, J. Price, S. Martin, K. Metcalfe, R. Krile et al., Characterization of 478 a Cynomolgus Macaque Model of Pneumonic Plague for Evaluation of Vaccine Efficacy. 479 Clinical and vaccine immunology, CVI, vol.22, pp.1070-1078, 2015.

E. D. Williamson, P. M. Vesey, K. J. Gillhespy, S. M. Eley, M. Green et al., An IgG1 titre 481 to the F1 and V antigens correlates with protection against plague in the mouse model, Clinical and Experimental Immunology, vol.482, pp.107-121, 1999.

R. Salerno-goncalves and M. B. Sztein, Cell-mediated immunity and the challenges for 484 vaccine development, Trends Microbiol, vol.14, pp.536-578, 2006.

A. Derbise, C. Marín, A. , A. P. Blisnick, T. Huerre et al., An 486 encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic 487 plague, PLoS NTD, vol.6, p.1528, 2012.

D. Kitamura and K. Rajewsky, Targeted disruption of mu chain membrane exon causes loss 489 of heavy-chain allelic exclusion, Nature, vol.356, pp.154-160, 1992.

S. Chanteau, L. Rahalison, L. Ralafiarisoa, J. Foulon, M. Ratsitorahina et al., Development and testing of a rapid diagnostic test for bubonic and pneumonic 492 plague, Lancet, vol.361, pp.211-217, 2003.

C. Benoit, A. Guiyoule, and E. Carniel, Sérodiagnostic des infections humaines à Yersinia 494 pathogènes, Presse Méd, vol.25, pp.1627-1657, 1996.

T. Michiels, P. Wattiau, R. Brasseur, J. M. Ruysschaert, and G. Cornelis, Secretion of Yop 496 Proteins by Yersiniae, Infection and Immunity, vol.58, pp.2840-2849, 1990.

W. D. Lawton, R. L. Erdman, and M. J. Surgalla, Biosynthesis and purification of V and W 498 antigens in Pasteurella pestis, Journal of Immunology, vol.91, pp.179-84, 1963.

Y. Flashner, M. Fisher, A. Tidhar, A. Mechaly, D. Gur et al., The search for 500 early markers of plague: evidence for accumulation of soluble Yersinia pestis LcrV in 501 bubonic and pneumonic mouse models of disease, FEMS Immunol Med Microbiol, vol.502, pp.197-206, 2010.

J. S. Lin, L. W. Kummer, F. M. Szaba, and S. T. Smiley, IL-17 contributes to cell-mediated defense 504 against pulmonary Yersinia pestis infection, J Immunol, vol.186, pp.1675-84, 2011.

J. Bashaw, S. Norris, S. Weeks, S. Trevino, J. J. Adamovicz et al., Development of in 506 vitro correlate assays of immunity to infection with Yersinia pestis. Clinical and vaccine 507 immunology : CVI, vol.14, pp.605-621, 2007.

E. D. Williamson, Acellular vaccines against plague

S. Yersinia, . Biology, . Control, and . Hethersett, , pp.123-165, 2012.

M. Morton, H. S. Garmory, S. D. Perkins, A. M. O'dowd, K. F. Griffin et al., A 511 Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its 512 surface provides protection against plague in mice, Vaccine, vol.22, pp.2524-2556, 2004.

J. S. Mencher, S. R. Smith, T. D. Powell, D. T. Stinchcomb, J. E. Osorio et al., Protection of 514 black-tailed prairie dogs (Cynomys ludovicianus) against plague after voluntary consumption 515 of baits containing recombinant raccoon poxvirus vaccine, Infect Immun, vol.72, pp.5502-5507, 2004.

G. W. Anderson, P. L. Worsham, C. R. Bolt, G. P. Andrews, S. L. Welkos et al., 517 Protection of mice from fatal bubonic and pneumonic plague by passive immunization with 518 monoclonal antibodies against the F1 protein of Yersinia pestis, American Journal of Tropical 519 Medicine and Hygiene, vol.56, pp.471-474, 1997.

E. D. Williamson, S. M. Eley, K. F. Griffin, M. Green, P. Russell et al., A new 521 improved sub-unit vaccine for plague: the basis of protection, FEMS Immunol Med 522 Microbiol, vol.12, pp.223-253, 1995.

Y. Qiu, Y. Liu, Z. Qi, W. Wang, Z. Kou et al., Comparison of immunological 524 responses of plague vaccines F1+rV270 and EV76 in Chinese-origin rhesus macaque, Macaca 525 mulatta, Scand J Immunol, vol.72, pp.425-458, 2010.

L. E. Quenee, C. A. Cornelius, N. A. Ciletti, D. Elli, and O. Schneewind, Yersinia pestis caf1 527 variants and the limits of plague vaccine protection, Infection and Immunity, vol.76, pp.2025-528, 2008.

V. L. Braciale, M. Nash, N. Sinha, I. V. Zudina, and V. L. Motin, Correlates of Immunity Elicited 530 by Live Yersinia pestis Vaccine, National 531 Institutes of Allergy and Infectious Diseases, vol.1, pp.473-80, 2008.

W. Sun, S. Sanapala, J. C. Henderson, S. Sam, J. Olinzock et al., LcrV delivered 534 via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances 535 immunogenicity against pneumonic plague, Infect Immun, vol.82, pp.4390-404, 2014.

B. Li, D. S. Zhou, Z. Y. Wang, Z. Z. Song, H. Wang et al., Antibody profiling in plague 537 patients by protein microarray, Microbes and Infection, vol.10, pp.45-51, 2008.

R. W. Depaolo, F. M. Tang, I. Kim, M. Han, N. Levin et al., Toll-Like Receptor, vol.6

, Drives Differentiation of Tolerogenic Dendritic Cells and Contributes to LcrV-Mediated 540

, Plague Pathogenesis. Cell Host and Microbe, vol.4, pp.350-61, 2008.

D. G. Heath, G. W. Anderson, J. M. Mauro, S. L. Welkos, G. P. Andrews et al.,

, Protection Against Experimental Bubonic and Pneumonic Plague By a Recombinant Capsular 543 F1-V Antigen Fusion Protein Vaccine, Vaccine, vol.16, pp.1131-1138, 1998.

K. F. Meyer, D. C. Cavanaugh, P. J. Bartelloni, J. D. Marshall, and J. , Plague immunization. I. Past 545 and present trends, Journal of Infectious Diseases, vol.129, pp.13-21, 1974.

M. M. Levine and M. B. Sztein, Vaccine development strategies for improving immunization: 547 the role of modern immunology, Nat Immunol, vol.5, pp.460-464, 2004.

R. Nakajima and R. R. Brubaker, Association between virulence of Yersinia pestis and 549 suppression of gamma interferon and tumor necrosis factor alpha, Infection and Immunity, vol.550, pp.23-31, 1993.

P. Health-england, Live attenuated vaccines: avoid use in those who are clinically 552 immunosuppressed, p.553, 2016.

A. Lopez, X. Mariette, H. Bachelez, A. Belot, B. Bonnotte et al., Vaccination 554 recommendations for the adult immunosuppressed patient: A systematic review and 555 comprehensive field synopsis, J Autoimmun, vol.80, pp.10-27, 2017.

L. Pitt, Public workshop on 557 animal models and correlates of protection for plague vaccines, 2004.

G. Girard, Immunity in Plague. Acquisitions Supplied by 30 Years of Work on the 560 "Pasteurella Pestis Ev" (Girard and Robic) Strain, Biol Med (Paris), vol.52, pp.631-731, 1963.

A. F. Hallett, M. Isaacson, and K. F. Meyer, Pathogenicity and immunogenic efficacy of a live 562 attentuated plaque vaccine in vervet monkeys, Infect Immun, vol.8, pp.876-81, 1973.

S. Welkos, M. L. Pitt, M. Martinez, A. Friedlander, P. Vogel et al., Determination 564 of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-565 deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic 566 plague, Vaccine, vol.20, pp.2206-2220, 2002.

B. Rasoamanana, F. Leroy, P. Boisier, M. Rasolomaharo, P. Buchy et al., Field 568 evaluation of an immunoglobulin G anti-F1 enzyme-linked immunosorbent assay for 569 serodiagnosis of human plague in Madagascar, Clin Diagn Lab Immunol, vol.4, pp.587-91, 1997.

L. E. Quenee, N. A. Ciletti, D. Elli, T. M. Hermanas, and O. Schneewind, Prevention of pneumonic 571 plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or 572 F1-V vaccines, Vaccine, vol.29, pp.6572-83, 2011.

J. A. Chichester, K. Musiychuk, C. E. Farrance, V. Mett, J. Lyons et al., A single 574 component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic 575 plague, Vaccine, vol.27, pp.3471-3475, 2009.

P. Fellows, J. Adamovicz, J. Hartings, R. Sherwood, W. Mega et al., Protection in 577 mice passively immunized with serum from cynomolgus macaques and humans vaccinated 578 with recombinant plague vaccine (rF1V), Vaccine, vol.28, pp.7748-56, 2010.

V. A. Feodorova, L. V. Sayapina, and V. L. Motin, Assessment of Live Plague Vaccine 580

. Candidates, Vaccine Design Methods in Molecular Biology, p.581, 2016.